Cryptotanshinone Inhibits Bladder Cancer Cell Malignant Progression in a Lipopolysaccharide-Induced Inflammatory...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Bladder cancer (BC) is a prevalent malignancy of the urogenital system.
• The role of nucleotide-binding oligomerization domain and leucine-rich repeat and pyrin domain-containing protein 3 (NLRP3) in BC pathogenesis requires further elucidation.
• The inflammatory microenvironment significantly influences BC progression.

Purpose of the Study:

• To investigate the expression and role of NLRP3 in bladder cancer.
• To assess the effects of cryptotanshinone on BC malignant behaviors in an LPS-induced inflammatory environment.
• To determine if cryptotanshinone's effects are mediated through NLRP3 inhibition.

Main Methods:

• Immunohistochemistry was used to detect NLRP3 protein in 62 BC tissue specimens.
• NLRP3 mRNA and protein levels were analyzed in BC and normal urothelial cell lines.
• BC cells were treated with lipopolysaccharide (LPS) to simulate an inflammatory microenvironment, followed by cryptotanshinone incubation or NLRP3 cDNA transfection.

Main Results:

• High NLRP3 expression correlated with advanced BC features, including larger tumor size, muscle invasion, and metastasis.
• LPS treatment upregulated NLRP3 and inflammatory cytokines, enhancing BC cell viability, migration, and invasion.
• Cryptotanshinone treatment reduced NLRP3 and inflammatory cytokine levels, mitigating BC cell malignant progression, an effect reversed by NLRP3 overexpression.

Conclusions:

• NLRP3 exhibits potential oncogenic activity in bladder cancer.
• Cryptotanshinone demonstrates in vitro antitumor effects against BC, likely via inhibition of NLRP3 expression.
• Targeting NLRP3 represents a potential therapeutic strategy for bladder cancer.